Overview

Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

To determine if there is any difference in the presence of retinal deterioration in PD patients treated with pramipexole IR versus ropinirole as monitored by comprehensive ophthalmologic assessments from baseline to the end of study at two years.

Phase:

Phase 4

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Pramipexole
Ropinirole